Small intestinal bacterial overgrowth characterized by excessive methane production (>10 ppm on breath testing), now more accurately termed IMO (Intestinal Methane Overgrowth). Caused by overgrowth of Methanobrevibacter smithii (an archaeon, not a bacterium) producing methane gas that directly inhibits intestinal motility via suppression of acetylcholine release at neuromuscular junctions. Accounts for approximately 35% of SIBO cases and presents with constipation-predominant symptoms, distinguishing it from hydrogen SIBO's diarrheal phenotype.
Think of your small intestine as a conveyor belt factory where materials (food) need to move through at a steady pace. In methane SIBO, instead of bacteria running the show, you've got archaea—ancient single-celled organisms that are like the factory's rogue maintenance crew. These archaea (Methanobrevibacter smithii) consume hydrogen gas and carbon dioxide produced by other microbes, turning them into methane—like converting factory exhaust into sedative gas.
Here's the problem: methane acts like a brake pedal pressed on the conveyor belt. It blocks acetylcholine—the "go signal" that normally tells the intestinal muscles to contract and move things along. With the brake constantly engaged, the conveyor belt slows to a crawl. Food sits longer, fermentation continues at a slower pace (so you can actually tolerate more carbs than hydrogen SIBO patients), but nothing moves out. The backup creates bloating and fullness, like a traffic jam where cars aren't honking (less urgent symptoms) but nobody's going anywhere (constipation). Because transit is so slow, bile acids—the detergent needed to absorb fats—don't circulate properly, leading to mild fat malabsorption and potentially deficiencies in fat-soluble vitamins.
Methane SIBO develops through the following cascade:
Initiating factors → impaired motility (loss of migrating motor complex), prior antibiotic use, proton pump inhibitors, or anatomical abnormalities → small intestinal environment becomes hospitable to colonization
Archaeal overgrowth:
- Methanobrevibacter smithii colonizes small intestine (normally should be confined to colon)
- Consumes H₂ + CO₂ → produces CH₄ (methane) via methanogenesis pathway
- Methane accumulates in intestinal lumen (detectable on breath testing >10 ppm at any time point during 3-hour test)
Motility inhibition cascade:
graph TD
A[Methane CH4 production] --> B[Methane diffuses to enteric neuromuscular junctions]
B --> C[Inhibits acetylcholine release from myenteric plexus neurons]
C --> D[Reduced smooth muscle contraction]
D --> E[Slowed peristalsis and transit time]
E --> F[Constipation phenotype]
E --> G[Extended fermentation time]
G --> H[Bloating and distension]
E --> I[Reduced bile acid circulation]
I --> J[Mild fat malabsorption]
Molecular mechanism of motility inhibition:
- CH₄ → acts on myenteric plexus neurons → suppresses acetylcholine (ACh) vesicle release
- Reduced ACh → decreased M3 muscarinic receptor activation on smooth muscle
- Decreased calcium signaling → reduced muscle contractility → slowed transit (can slow transit by 59% compared to controls)
Secondary effects:
- Slow transit → incomplete bile acid reabsorption in terminal ileum → reduced enterohepatic circulation → mild steatorrhea
- Extended intestinal contact time → better carbohydrate tolerance (slower fermentation rate, more complete absorption)
- Methane itself is not directly inflammatory (unlike Hâ‚‚S), but stasis promotes immune activation
Diagnostic pathway:
- Lactulose or glucose breath test → methane measurement every 20 minutes for 3 hours
- Positive if CH₄ ≥10 ppm at ANY time point (different from hydrogen SIBO criteria)
- May see flat hydrogen curve (methanogens consume Hâ‚‚ produced by bacteria)
Patient presentation:
- Constipation-predominant IBS phenotype (as opposed to diarrhea in hydrogen SIBO)
- Chronic bloating and postprandial fullness (worse after meals, improves with fasting)
- Better tolerance of FODMAPs and carbohydrates compared to hydrogen SIBO patients
- May have history of chronic laxative use, opioid medications, or hypothyroidism (all slow motility)
Evolutionary/metamodel context:
This condition exemplifies modern mismatch—archaea like Methanobrevibacter evolved in our colons as hydrogen scavengers, part of normal fiber fermentation. Migration to the small intestine represents ecological displacement driven by: (1) antibiotics disrupting competitive bacteria, (2) PPIs creating favorable pH, (3) sedentary lifestyle reducing MMC activity, (4) processed low-fiber diets failing to maintain normal colonic transit. The selfish microbiome prioritizes its own survival (consuming available H₂) at the expense of host motility.
Diagnostic thresholds:
- Methane >10 ppm = diagnostic for IMO
- Methane 3-10 ppm = "intestinal methane production" (may still be clinically significant)
- Flat hydrogen curve with elevated methane suggests methanogen dominance
- Constipation severity often correlates with methane levels (>15 ppm = more severe)
Intervention strategy:
Unlike hydrogen SIBO, methane SIBO requires archaea-specific antimicrobials:
- Allicin (garlic extract) 450mg 3x/day for 4 weeks—primary agent, disrupts archaeal cell membranes
- Neem extract 300mg 2x/day—synergistic archaeal inhibition
- Oregano oil and berberine (standard SIBO herbs) are LESS effective against archaea
- Prokinetics essential: ginger 1000mg/day, iberogast 20 drops 3x/day, low-dose naltrexone 1-4.5mg nightly (restores migrating motor complex)
Dietary approach differs from Hâ‚‚ SIBO:
- Fiber restriction LESS critical (slow fermentation means better tolerance)
- May benefit from insoluble fiber to mechanically stimulate motility
- Low-FODMAP helpful but not as essential as in hydrogen SIBO
- Emphasize prokinetic foods: ginger, bitter greens, coffee (in tolerance)
Three-phase protocol:
- Restrict + treat: modified low-FODMAP + allicin/neem 4 weeks
- Reintroduce slowly: assess tolerance with gradual fiber increase
- Restore motility: lifelong prokinetic support, address root cause (thyroid, opioids, stress affecting MMC)
- 35% of SIBO cases are methane-predominant; remaining split between hydrogen (50-60%) and hydrogen sulfide (5-10%)
- Diagnosis requires methane ≥10 ppm at ANY single time point during 3-hour breath test (not rise from baseline)
- Caused by Methanobrevibacter smithii archaea, NOT bacteria—explains why standard antibiotics often fail
- Methane directly inhibits acetylcholine release at myenteric plexus, slowing transit by up to 59%
- Presents with constipation (opposite of hydrogen SIBO's diarrhea)—this is exam-critical differentiation
- Better carbohydrate tolerance than hydrogen SIBO due to slower fermentation rate
- Slow transit reduces bile acid circulation → mild fat malabsorption and potential vitamin D, A, E, K deficiency
- Treatment: Allicin 450mg 3x/day + Neem 300mg 2x/day for 4 weeks (oregano less effective for archaea)
- Prokinetics mandatory to restore migrating motor complex: ginger, iberogast, low-dose naltrexone
- Diet less restrictive than hydrogen SIBO; may benefit from insoluble fiber to stimulate mechanical motility
- Flat hydrogen curve with elevated methane suggests methanogens are consuming Hâ‚‚ produced by bacteria
- Risk factors: PPI use, opioids, hypothyroidism, prior antibiotics, sedentary lifestyle, adhesions/anatomical obstruction
- IMO — IMO (Intestinal Methane Overgrowth) is the current preferred terminology, replacing "methane SIBO" to reflect archaeal rather than bacterial etiology
- Methanobrevibacter smithii — the primary archaeal species causing methane SIBO, consumes H₂ and CO₂ to produce methane
- methane — methane gas production ≥10 ppm on breath testing is the defining diagnostic criterion
- methanogens — archaea (not bacteria) that produce methane, explaining resistance to standard antibacterial SIBO treatments
- SIBO — methane SIBO represents one of three major phenotypes (hydrogen, methane, hydrogen sulfide) requiring distinct treatment approaches
- hydrogen SIBO — presents with opposite symptoms (diarrhea vs constipation) due to different gas effects on motility
- hydrogen sulfide SIBO — third SIBO phenotype producing H₂S gas, often overlaps with methane SIBO
- constipation — hallmark symptom caused by methane's suppression of acetylcholine and resultant hypomotility
- breath testing — lactulose or glucose breath test measuring methane every 20 minutes is diagnostic standard
- allicin — garlic-derived compound, 450mg 3x/day is first-line antimicrobial for archaeal eradication
- Neem — Neem extract 300mg 2x/day synergizes with allicin for archaeal suppression
- oregano oil — less effective against archaea than bacteria, secondary choice in methane SIBO protocols
- prokinetics — essential to restore migrating motor complex and prevent relapse (ginger, iberogast, low-dose naltrexone)
- bile acids — slow intestinal transit impairs enterohepatic circulation, causing mild fat malabsorption
- bloating — results from methane accumulation and prolonged fermentation time in small intestine
- fiber — unlike hydrogen SIBO, fiber restriction less critical; insoluble fiber may aid mechanical motility
- acetylcholine — neurotransmitter suppressed by methane at neuromuscular junctions, causing dysmotility
- migrating motor complex — interdigestive "housekeeping wave" essential to prevent bacterial/archaeal overgrowth, often impaired in methane SIBO
- IBS — methane SIBO often underlies IBS-C (constipation-predominant) phenotype
- PPIs — proton pump inhibitors increase methane SIBO risk by altering pH and reducing gastric antimicrobial barrier
- low-FODMAP diet — helpful but less essential than in hydrogen SIBO due to slower fermentation and better carb tolerance
- fat malabsorption — occurs due to impaired bile acid circulation from slow transit, may cause deficiency in vitamins D, A, E, K
- microbiome — methane SIBO represents ecological dysbiosis with archaeal displacement from colon to small intestine